NasdaqGS:ACRSPharmaceuticals
Aclaris Therapeutics (ACRS) Halved TTM Losses Test Bearish Unprofitability Narratives
Aclaris Therapeutics FY 2025 results in focus
Aclaris Therapeutics (ACRS) just closed out FY 2025 with Q4 total revenue of US$1.3 million, basic EPS of a US$0.16 loss, and net income loss excluding extra items of US$19.8 million, setting a clear tone for how the year wrapped up. The company has seen quarterly revenue move from US$9.2 million in Q4 2024 to US$1.3 million in Q4 2025, while basic EPS shifted from a US$1.01 loss to a US$0.16 loss over the same period. This gives investors a...